BD Boston
Date: Location: Cost:
September 4, 2018 Hilton Boston Back Bay
40 Dalton Street
Boston, MA 02115

Starting at $1950


Dress Code:
Business Attire


BD BOSTON - September 4, 2018

2018 Steering Committee Members:
Kees BeenCEO, Lysosomal Therapeutics; Rakhshita DharBusiness Development, Roche; Chris GarabedianChairman & CEO, Xontogeny; John HallinanCBO, MassBio; Arthur HillerCEO, Antyllus Therapeutics; Phil McGurkBusiness Development Lead, Pfizer; Imran NasrullahDirector, Boehringer Ingelheim; Ramani VaranasiPresident & CEO, X-Biotix Therapeutics

Confirmed speakers include:
Yuval CohenCEO, Corbus Pharma; David H. DonabedianCo-Founder & CEO, Axial Biotherapeutics; Kris ElverumChief Business Officer, Turnstone Biologics; Christopher GuiffreCFO & COO, Pear Therapeutics; Kate HavilandCBO, Blueprint Medicines; Jennifer KingVP Business Development, Intellia Therapeutics; Philippe Lopes-FernandesSVP, Global Head of Licensing, BD & Alliance Management, EMD Serono; Christoph WestphalCo-Founder & Partner, Longwood Fund

Time Agenda
7:00-8:00 am

Registration and Networking Breakfast

8:00-8:15 am

Welcome and Opening Remarks
John Westwood,
Managing Director Huron

8:15-8:45 am

The Impact of Changes in Tax Law on Corporate Strategy & Development

8:45-9:30 am

Defining your BD Strategy vs. Opportunism - Consistent Corporate Vision
Susan GrafCBO, Epizyme; Jonathan P. Lanfear, Global Head, Oncology and Neuroscience Business Development, Takeda Pharmaceuticals International, Inc; Philippe Lopes-FernandesSVP, Global Head of Licensing, BD & Alliance Management, EMD Serono; Phil McGurk, Business Development Lead, Inflammation & Immunology, Pfizer
Moderator: Kate Haviland, CBO, Blueprint Medicines

9:30-10:00 am

Networking Break

10:00-10:30 am

Alternative Capital Sources
Constantine Chinoporos, CBO, Boston Pharmaceuticals; Yuval Cohen, CEO, Corbus Pharma
Moderator: Christopher de SouzaDirectorBroadview Ventures

10:30-10:40 am

Spotlight Focus: Axial Biotherapeutics
David H. DonabedianCo-Founder & CEO, Axial Biotherapeutics

10:40-11:15 am

VC Investments: Raising Capital
David GiljohannCEO, Exicure; David H. DonabedianCo-Founder & CEO, Axial Biotherapeutics; 
Moderator: Steven MermelsteinManaging Director, Huron Transaction Advisory 

11:15-11:25 am

Spotlight Focus: Turnstone Biologics
Kris ElverumChief Business Officer, Turnstone Biologics

11:25-12:00 pm

Small Biotech & Pharma Partnering
Kris Elverum, Chief Business Officer, Turnstone Biologics; Micah Mackison, VP, Corporate Development & Strategy, Assembly Biosciences; Torsten Mummenbrauer, SVP Business Development & Licensing, Hookipa Pharma Inc.
Moderator: Imran NasrullahDirector, Strategic Partnering, BD&L, Boehringer Ingelheim Pharmaceuticals 

12:00-1:00 pm

Networking Lunch

1:00-1:30 pm

Creative Deal Structures
Rodolphe Clerval, CBO, Enterome; Kia Motesharei, Head of BD Neurology & Immunology, EMD Serono; John D. Quisel, CBO, Acceleron Pharma
Moderator: Ramani Varanasi, President & CEO, X-Biotix Therapeutics 

1:30-2:00 pm

When to Think Commercial?
Jean-Sebastien Cleiftie, CBO, Erytech Pharma; Jennifer King, VP Business Development, Intellia Therapeutics
Moderator: Marc Tomassi, Managing Director, Huron Life Sciences

2:00-2:30 pm

So Your World Just Changed, How do you Fix It? Re-Negotiating The Deal
Moderator: Arthur Hiller, CEO, Antyllus Therapeutics

2:30-3:00 pm

Fireside Chat
Christoph WestphalCo-Founder & Partner, Longwood Fund

3:00-3:30 pm

Networking Break

3:30-4:00 pm

The Impact of Novel Modalities: Deal-Making in the Era of Disruptive Technologies  
Christopher Guiffre
, CFO & COO, Pear Therapeutics; Vincent Hennemand SVP Strategy, Corporate and Business Development, Akili Interactive Labs Todd Smith, CEO, Novum Pharma
Moderator: David Moller, CSO, Sigilon Therapeutics

4:00-4:30 pm

The New Frontier in Academic Partnering: New Models for Mutually Beneficial Collaborations
Moderator: James Zanewicz, Chief Business Officer, Tulane University School of Medicine

4:30-5:00 pm

The Future of Deal-Making & Partnerships: 2018 and Beyond
Ivana Magovcevic-Liebisch, EVP, Chief Business Officer, Ipsen

5:00-5:10 pm

Closing Remarks
Rakshita Dhar, Business Development, Roche 

5:10-6:10 pm

Cocktails and Hors d'oeuvres

Executive Sponsors: (see all sponsors)